RCVS

Mars Veterinary Health pilots industry-leading anaesthetic gas capture technology to reduce carbon emissions

Retrieved on: 
Wednesday, April 3, 2024
Sustainability, Waltham Petcare Science Institute, Incineration, Environment, Partnership, History, Carbon, Carl Linnaeus, Pet, RCVS

BIRMINGHAM, England, April 3, 2024 /PRNewswire/ -- Mars Veterinary Health, through its UK veterinary group Linnaeus and in partnership with Waltham Petcare Science Institute, today announced a first-of-its-kind partnership with SageTech Veterinary to pilot an innovative anaesthetic gas capture solution to help prevent harmful greenhouse gases from entering the atmosphere. 

Key Points: 
  • BIRMINGHAM, England, April 3, 2024 /PRNewswire/ -- Mars Veterinary Health , through its UK veterinary group Linnaeus and in partnership with Waltham Petcare Science Institute , today announced a first-of-its-kind partnership with SageTech Veterinary to pilot an innovative anaesthetic gas capture solution to help prevent harmful greenhouse gases from entering the atmosphere.
  • These waste anaesthetic agents can then be extracted from the filter, avoiding current routes for disposal of volatile anaesthetic agents of incineration or release into the atmosphere.
  • Mars Veterinary Health aims to use these learnings to explore the potential application of this technology across other parts of its business in the years to come.
  • "At SageTech Veterinary, we are excited to share our developed technology and work alongside Mars Veterinary Health to significantly reduce the carbon footprint associated with the direct release of waste volatile anaesthetic agents to the environment," said Iain Menneer, CEO of SageTech Medical.

Mars Veterinary Health pilots industry-leading anaesthetic gas capture technology to reduce carbon emissions

Retrieved on: 
Wednesday, April 3, 2024
Sustainability, Waltham Petcare Science Institute, Incineration, Environment, Partnership, History, Carbon, Carl Linnaeus, Pet, RCVS

BIRMINGHAM, England, April 3, 2024 /PRNewswire/ -- Mars Veterinary Health, through its UK veterinary group Linnaeus and in partnership with Waltham Petcare Science Institute, today announced a first-of-its-kind partnership with SageTech Veterinary to pilot an innovative anaesthetic gas capture solution to help prevent harmful greenhouse gases from entering the atmosphere. 

Key Points: 
  • BIRMINGHAM, England, April 3, 2024 /PRNewswire/ -- Mars Veterinary Health , through its UK veterinary group Linnaeus and in partnership with Waltham Petcare Science Institute , today announced a first-of-its-kind partnership with SageTech Veterinary to pilot an innovative anaesthetic gas capture solution to help prevent harmful greenhouse gases from entering the atmosphere.
  • These waste anaesthetic agents can then be extracted from the filter, avoiding current routes for disposal of volatile anaesthetic agents of incineration or release into the atmosphere.
  • Mars Veterinary Health aims to use these learnings to explore the potential application of this technology across other parts of its business in the years to come.
  • "At SageTech Veterinary, we are excited to share our developed technology and work alongside Mars Veterinary Health to significantly reduce the carbon footprint associated with the direct release of waste volatile anaesthetic agents to the environment," said Iain Menneer, CEO of SageTech Medical.

Meeting highlights from the Committee for Medicinal Products for Human Use (CHMP) 22-25 January 2024

Retrieved on: 
Sunday, February 4, 2024
Civil service commission, Pneumonia, Febrile neutropenia, Eli Lilly, Triprolidine, International, Bacteria, Schizophrenia, Myelopathy, Incidence, ALD, Cefepime, Allergic rhinitis, Nasal congestion, Neutrophil, Agency, COMP, Fever, HAP, EEIG, Headache, Static pressure, Medicine, Committee, Conditional, Spinal cord, Hospital-acquired pneumonia, PTC, Neutropenia, Public, CHMP, European, AMD, Patient, Diagnosis, Marketing, RCVS, European Commission, Brain, Disease, Infection, Inflammation, Male, PRES, PRAC, Pain, Pyelonephritis, Urinary tract infection, VAP, Ageing, EMA, Geographic atrophy, Adrenoleukodystrophy, Therapy, News, INN, Duchenne muscular dystrophy, Common, Fungal infection, Vaccine

Three new medicines recommended for approvalEMA’s human medicines committee (CHMP) recommended three medicines for approval at its January 2024 meeting.The committee recommended…, Positive recommendations on new medicines, Exblifep International non-proprietary name (INN)cefepime / enmetazobactam Marketing-authorisation applicantAdvanz Pharma LimitedTherapeutic indicationTreatment of: 1)…, Ryzneuta INNefbemalenograstim alfaMarketing-authorisation applicantEvive Biotechnology Ireland LimitedTherapeutic indicationReduction in the duration of neutropenia and…, Positive recommendations on new generic medicines, Niapelf INNpaliperidoneMarketing-authorisation applicantNeuraxpharm Pharmaceuticals S.L.Therapeutic indicationTreatment of schizophreniaMore informationNiapelf: Pending…, Negative recommendations on new medicines, Nezglyal INNleriglitazoneMarketing-authorisation applicantMinoryx Therapeutics S.L.Therapeutic indicationTreatment of cerebral progression and myelopathy in male…, Syfovre INNpegcetacoplanMarketing-authorisation applicantApellis Netherlands B.V.Therapeutic indicationTreatment of geographic atrophy (GA) secondary to age-related…, Positive recommendations on extensions of indications, Abecma INNidecabtagene vicleucel Marketing-authorisation holderBristol-Myers Squibb Pharma EEIGMore informationAbecma: Pending EC decision, Prevenar 20 (previously Apexxnar) Common namepneumococcal polysaccharide conjugate vaccine (20-valent, adsorbed)Marketing-authorisation holderPfizer Europe MA EEIGMore…, Aspaveli INNpegcetacoplanMarketing-authorisation holderSwedish Orphan Biovitrum AB (publ)More informationAspaveli: Pending EC decision, Retsevmo INNselpercatinibMarketing-authorisation holderEli Lilly Nederland B.V.More informationRetsevmo: Pending EC decision, Outcome of re-examination of recommendation on non-renewal of Conditional Marketing Authorisation, Translarna INNataluren Marketing-authorisation holderPTC Therapeutics International LimitedNewsEMA confirms recommendation for non-renewal of authorisation of Duchenne…, Outcome of referral, Pseudoephedrine Marketing-authorisation holderVarious companiesMore informationPseudoephedrine-containing medicinal products, Re-examination of conclusion of referral, Synapse Labs Pvt.

Key Points: 
  • Three new medicines recommended for approvalEMA’s human medicines committee (CHMP) recommended three medicines for approval at its January 2024 meeting.The committee recommended…, Positive recommendations on new medicines, Exblifep International non-proprietary name (INN)cefepime / enmetazobactam Marketing-authorisation applicantAdvanz Pharma LimitedTherapeutic indicationTreatment of: 1)…, Ryzneuta INNefbemalenograstim alfaMarketing-authorisation applicantEvive Biotechnology Ireland LimitedTherapeutic indicationReduction in the duration of neutropenia and…, Positive recommendations on new generic medicines, Niapelf INNpaliperidoneMarketing-authorisation applicantNeuraxpharm Pharmaceuticals S.L.Therapeutic indicationTreatment of schizophreniaMore informationNiapelf: Pending…, Negative recommendations on new medicines, Nezglyal INNleriglitazoneMarketing-authorisation applicantMinoryx Therapeutics S.L.Therapeutic indicationTreatment of cerebral progression and myelopathy in male…, Syfovre INNpegcetacoplanMarketing-authorisation applicantApellis Netherlands B.V.Therapeutic indicationTreatment of geographic atrophy (GA) secondary to age-related…, Positive recommendations on extensions of indications, Abecma INNidecabtagene vicleucel Marketing-authorisation holderBristol-Myers Squibb Pharma EEIGMore informationAbecma: Pending EC decision, Prevenar 20 (previously Apexxnar) Common namepneumococcal polysaccharide conjugate vaccine (20-valent, adsorbed)Marketing-authorisation holderPfizer Europe MA EEIGMore…, Aspaveli INNpegcetacoplanMarketing-authorisation holderSwedish Orphan Biovitrum AB (publ)More informationAspaveli: Pending EC decision, Retsevmo INNselpercatinibMarketing-authorisation holderEli Lilly Nederland B.V.More informationRetsevmo: Pending EC decision, Outcome of re-examination of recommendation on non-renewal of Conditional Marketing Authorisation, Translarna INNataluren Marketing-authorisation holderPTC Therapeutics International LimitedNewsEMA confirms recommendation for non-renewal of authorisation of Duchenne…, Outcome of referral, Pseudoephedrine Marketing-authorisation holderVarious companiesMore informationPseudoephedrine-containing medicinal products, Re-examination of conclusion of referral, Synapse Labs Pvt.
  • Ltd. Marketing-authorisation holderVarious companiesMore informationSynapse

Meeting highlights from the Pharmacovigilance Risk Assessment Committee (PRAC) 27-30 November 2023

Retrieved on: 
Monday, December 18, 2023
Medicine, Vomiting, Brain, Liraglutide, European Commission, Pseudoephedrine, Semaglutide, RCVS, PRES, Headache, Dulaglutide, Allergy, Kidney disease, State, EMA, Civil service commission, Signal, Patient, DSM-IV codes, Exenatide, Association, RMP, Vaccine, CHMP, Reversible cerebral vasoconstriction syndrome, Marketing, Data, COVID-19, Seizure, Diagnosis, Communication, Direct, Health care, Review, Failure, PRAC, Confusion, Public, Pharmaceutical industry, Hospital, Dietary supplement, Medical device, Safety

EMA’s safety committee, PRAC, has recommended new measures for medicines containing pseudoephedrine to minimise the risks of posterior reversible encephalopathy syndrome (PRES)…, Agenda Agenda of the PRAC meeting 27-30 November 2023DraftFirst published: 27/11/2023Reference Number: EMA/PRAC/477373/2023…, PRAC statistics: December 2023, Glossary:Safety signal assessments. A safety signal is information which suggests a new potentially causal association, or a new aspect of a known association between a medicine…, Ongoing referralsProcedureStatusUpdateHydroxyprogesterone-containing medicinal products – Article-31 referralUnder evaluationPRAC continued its assessment

Key Points: 


EMA’s safety committee, PRAC, has recommended new measures for medicines containing pseudoephedrine to minimise the risks of posterior reversible encephalopathy syndrome (PRES)…, Agenda Agenda of the PRAC meeting 27-30 November 2023DraftFirst published: 27/11/2023Reference Number: EMA/PRAC/477373/2023…, PRAC statistics: December 2023, Glossary:Safety signal assessments. A safety signal is information which suggests a new potentially causal association, or a new aspect of a known association between a medicine…, Ongoing referralsProcedureStatusUpdateHydroxyprogesterone-containing medicinal products – Article-31 referralUnder evaluationPRAC continued its assessment

TOO HOT TO TROT: PETPLAN LAUNCHES FIRST-OF-ITS-KIND DIGITAL "WEATHER FURCAST" FOR DOG OWNERS, AS MINI HEATWAVE HITS UK THIS WEEK

Retrieved on: 
Thursday, August 24, 2023
RCVS, Human, Fetch by the Dodo, Amber, Spasm, Dehydration, Biting, Research, Temperature, Heat stroke, Heat, Walking, Weather, Swelling, Map, Dog, Rabbit, Bank, Veterinary surgery, Cat, Livestock, Pet industry, Trapping, Furcaster

To lend a helping hand to dog owners everywhere, Petplan has launched a first-of-its-kind interactive " Weather Fur cast " for dogs*.

Key Points: 
  • To lend a helping hand to dog owners everywhere, Petplan has launched a first-of-its-kind interactive " Weather Fur cast " for dogs*.
  • The digital tool, hosted on Petplan.co.uk updates in real time to show when is and isn't safe to walk your dog, helping dog owners make safe choices this summer.
  • Whilst this feels logical, the real danger to dogs lies in the temperature, not whether or not it's sunny, although this still plays a part.
  • 70% of UK dog owners are concerned about the effect rising temperatures will have on their furry friends.

Global 5G In Defense Market Report 2022: A $1098.69 Million Market in 2026, Growing at a CAGR of 70.4% - Long-term Forecast to 2031

Retrieved on: 
Wednesday, June 22, 2022
IED, Solution, Ligado Networks, Industry, United States Army, MMTC, Navy, NEC, MEC, AT&T, Intelligence, Raytheon Technologies, Method, Technology, RAN, URLLC, Army of the United States, Samsung, Federation, FAS, Efficiency, 5G, RCVS, Nokia Networks, Telecommunication, Community Infrastructure Fund, Growth, FC, RAIL, National, Ericsson, L3Harris Technologies, NFV, Artificial intelligence, Data, Partnership, Huawei, Communication, Speech, Thales Group, AT, MAK Technologies, Inc., NR, Organization, Weapon, Satellite navigation device

The main types of communication infrastructure for 5G in defense are small cell, macro cell, radio access network (RAN).

Key Points: 
  • The main types of communication infrastructure for 5G in defense are small cell, macro cell, radio access network (RAN).
  • The various network technology in 5G in defense include software-defined networking (SDN), fog computing (FC), mobile edge computing (MEC), network functions virtualization (NFV).
  • The increasing use of autonomous systems and connected devices is expected to propel the growth of 5G in defense market during the forecast period.
  • The concern over data security acted as a restraint for the 5G in defense market in the historic period.

Global $130+ Billion 5G In Defense Markets, 2016-2021, 2026, 2031F by Communication Infrastructure, Core Network Technology, Network Type, End Use - ResearchAndMarkets.com

Retrieved on: 
Monday, June 20, 2022
Mobile, Wireless, Technology, 5G, IED, Solution, Ligado Networks, Industry, United States Army, MMTC, Navy, NEC, MEC, AT&T, Intelligence, Raytheon Technologies, Method, Technology, RAN, URLLC, Army of the United States, Samsung, Federation, FAS, Efficiency, 5G, RCVS, Nokia Networks, Telecommunication, Community Infrastructure Fund, Growth, FC, RAIL, National, Ericsson, L3Harris Technologies, NFV, Artificial intelligence, Data, Partnership, Huawei, Communication, Speech, Thales Group, AT, MAK Technologies, Inc., NR, Organization, Weapon, Satellite navigation device

The "5G In Defense Global Market Report 2022, By Communication Infrastructure, Core Network Technology, Network Type, End Use" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "5G In Defense Global Market Report 2022, By Communication Infrastructure, Core Network Technology, Network Type, End Use" report has been added to ResearchAndMarkets.com's offering.
  • The main types of communication infrastructure for 5G in defense are small cell, macro cell, radio access network (RAN).
  • The various network technology in 5G in defense include software-defined networking (SDN), fog computing (FC), mobile edge computing (MEC), network functions virtualization (NFV).
  • The 5G network is said to have increased the efficiency of autonomous systems by providing faster speeds and greater bandwidth.

Heil and Boivin Evolution Inc. are Propelling Refuse Collection into a Lower-Carbon Future

Retrieved on: 
Thursday, April 7, 2022
LinkedIn, Partnership, Sale, Automation, Overalls, Ownership, ESG, RCV, NOx, Environment, Technology, Twitter, RCVS, Facebook, CNG, BEV, Efficiency, Maintenance, Acquisition, Collection, Cryptocurrency, Heavy equipment

Heil and BEV will also jointly collaborate in the development of future electric-powered refuse collection technologies.

Key Points: 
  • Heil and BEV will also jointly collaborate in the development of future electric-powered refuse collection technologies.
  • Their refuse collection bodies include a wide variety of front loaders, side loaders, and rear loaders.
  • For more information about Heil, visit heil.com , the Heil Facebook page or follow Heil on Twitter .
  • Founded in 2017 and located in Levis, Qubec, Boivin Evolution specializes in designing and manufacturing all types of all-electric refuse collection bodies.

Dover Completes Acquisition of Electric Refuse Collection Vehicle Intellectual Property Portfolio

Retrieved on: 
Wednesday, April 6, 2022
Plastech Engineered Products, Adoption, Private Securities Litigation Reform Act, Company, Heil Environmental Industries, Pandemic, Körber Process Solutions, Climate, Sumathi Best Television Current Reporting Award, Leadership, Sustainable Technology Optimization Research Center, Forward-looking statement, NYSE, ESG, SEC, RCV, Recycling, U.S. Securities and Exchange Commission, Software, Industry, DOV, Technology, Marathon, COVID-19, RCVS, Solution, BEV, Third eye, Annual report, New, Acquisition, Municipal solid waste, Security (finance), Lithium

DOWNERS GROVE, Ill., April 6, 2022 /PRNewswire/ -- Dover (NYSE: DOV) today announced that it has completed the acquisition of certain intellectual property from Boivin Evolution Inc. ("BEV") related to electrically-powered refuse collection vehicle ("RCV") bodies.

Key Points: 
  • DOWNERS GROVE, Ill., April 6, 2022 /PRNewswire/ -- Dover (NYSE: DOV) today announced that it has completed the acquisition of certain intellectual property from Boivin Evolution Inc. ("BEV") related to electrically-powered refuse collection vehicle ("RCV") bodies.
  • The acquisition will enhance and solidify the technological leadership and product portfolio of Dover's Environmental Solutions Group ("ESG") business unit within Dover's Engineered Products segment.
  • "ESG is a global leader in solutions for the waste and recycling industries and a recognized technology pioneer.
  • Dover is a diversified global manufacturer and solutions provider with annual revenue of approximately $8 billion.

Sauro-Throat! First evidence of dinosaur respiratory infection

Retrieved on: 
Thursday, February 10, 2022
Urinary tract infection, Weight loss, Bone growth factor, Degenerative disease, Dennison, RCVS, Great Plains Dinosaur Museum and Field Station, Respiratory system, Aspergillosis, Breathe Me, BVM, Infection, Jurassic, MRCVS, College of Osteopathic Medicine of the Pacific, Bird, Doctor of Philosophy, Neck, DVM, Western University, Western University College of Podiatric Medicine, Death, Thought, College, Yolk sac, Pacific Ocean, Skeleton, Cough, Fever, Cervical vertebrae, Mycosis, Osteopathic medicine in the United States, Mesozoic, Podiatry, Osteomyelitis, University of New Mexico, Dropbox, Associate, University, News, Western University of Health Sciences, Scientific Reports, Dinosaur, Dolly, Reptile, Outline of health sciences, Dentistry, Vaccine, Poultry

POMONA, Calif., Feb. 10, 2022 /PRNewswire-PRWeb/ --The fossilized remains of an immature diplodocid a large, long- necked herbivorous sauropod dinosaur, like "Brontosaurus" may provide the first evidence of a unique respiratory infection in a dinosaur, according to a study published in Scientific Reports.

Key Points: 
  • POMONA, Calif., Feb. 10, 2022 /PRNewswire-PRWeb/ --The fossilized remains of an immature diplodocid a large, long- necked herbivorous sauropod dinosaur, like "Brontosaurus" may provide the first evidence of a unique respiratory infection in a dinosaur, according to a study published in Scientific Reports.
  • These air sacs would have ultimately connected to "Dolly's" lungs and formed part of the dinosaur's complex respiratory system.
  • The authors speculate that this respiratory infection could have been caused by a fungal infection similar to aspergillosis, a common respiratory illness that affects birds and reptiles today and can lead to bone infections.
  • In addition to documenting the first occurrence of such a respiratory infection in a dinosaur, this fossilized infection also has important anatomical implications for the respiratory system of sauropod dinosaurs.